Literature DB >> 10484751

Structural analysis of adeno-associated virus transduction circular intermediates.

D Duan1, Z Yan, Y Yue, J F Engelhardt.   

Abstract

Recombinant adeno-associated virus (rAAV) has recently been demonstrated to form circular intermediates following transduction in muscle tissue and cell lines. Although restriction enzyme and Southern blot analysis has revealed a consistent monomer and multimer head-to-tail conformation, detailed structural sequence analysis has been lacking due to the high secondary structure of the ITR arrays. To gain further insight into potential mechanisms by which AAV circular genomes are formed from linear single-stranded viral DNA, we have performed chemical sequencing of ITR arrays within seven circular intermediates independently isolated from primary fibroblasts and Hela cells. Results from these studies demonstrated several types of circular intermediates with mosaic ITR elements flanked by two D sequences. The most predominant form consisted of a structure similar to that of previously generated AAV double-D plasmids, with one complete ITR flanked by two D-region elements. However, intermediately deleted ITR arrays with more than one complete ITR were also seen. Based on this structural information, we have proposed a model for formation of AAV circular intermediates by recombination/ligation between ITR ends of panhandle single-stranded AAV genomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484751     DOI: 10.1006/viro.1999.9821

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids.

Authors:  L Cao; Y Liu; M J During; W Xiao
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes.

Authors:  Marcela P Cataldi; Douglas M McCarty
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 5.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

6.  Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction.

Authors:  Jinhui Wang; Jing Xie; Hui Lu; Lingxia Chen; Bernd Hauck; Richard Jude Samulski; Weidong Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

7.  Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes.

Authors:  Ziying Yan; Roman Zak; Yulong Zhang; John F Engelhardt
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 8.  Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.

Authors:  Kyle Chamberlain; Jalish Mahmud Riyad; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2016-02       Impact factor: 2.396

9.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

10.  Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks.

Authors:  Daniel G Miller; Lisa M Petek; David W Russell
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.